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SocietyDr Sowers brings up an interesting issue related to our prior
publication1 on delayed gadolinium-enhanced magnetic
resonance imaging of cartilage (dGEMRIC) and body
mass index (BMI). She suggests that a dose-bias correction
in dGEMRIC should be based upon skeletal muscle mass
rather than BMI. We appreciate the general points made,
and look forward to seeing more of the data regarding
body composition as it relates to osteoarthritis (OA) in her
upcoming paper. However, the Letter, in discussing body
composition and OA, seems to be confusing the two as-
pects of the original paper: First, the correction of dGEMRIC
data due to a contrast agent dose bias with BMI; second,
dGEMRIC as a function of BMI after dose correction, i.e.,
study of OA itself.
The parameter of interest in terms of contrast agent dose
in the dGEMRIC technique is the blood level of contrast
agent, as that is what will provide the source of contrast
agent to the cartilage. When dosing gadolinium-diethylene-
triamine pentaacetic acid (Gd(DTPA)2) (Magnevist; Ber-
lex, NJ) by total body weight, the blood level might vary
with BMI since the contrast agent distributes into all extra-
cellular ﬂuid, and adipose tissue has a generally different
percent extracellular ﬂuid relative to other tissues.
The blood level of the MRI contrast agent Gd(DTPA)2
was measured directly as a function of BMI in our earlier
study1. The experimental data directly determined the rec-
ommended compensation factor to correct for differing
blood level of contrast agent due to dosing of the contrast
agent by weight. The fact that our curves matched those pre-
dicted from prior measurements of extracellular water as
a function of BMI2 further supports this general approach.
Dr Sowers recommends using bioelectric impedance or
dual X-ray densitometry (DEXA) for measuring muscle
mass, and utilizing that as a correction for dose bias in
dGEMRIC. It is possible that one of these techniques would
be better estimate of extracellular water volume than using
BMI as an index. However, to answer this question, the
correlation between bioelectric impedance (and DEXA)
and plasma Gd(DTPA)2 levels needs to be established.
In addition, neither of these techniques is readily available
clinically.
Therefore, we stand by our earlier assertion that BMI is
a reasonable ‘‘ﬁrst order’’ correction for those cross-sec-
tional studies in which there is a very large range of BMI,
or if BMI changes over time in a longitudinal study. We
stress again that dose bias is probably not relevant in
many of the ongoing studies of dGEMRIC, and the
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harvard.edu59correction factor did not alter conclusions when retrospec-
tively implemented in a prior study of dGEMRIC in OA1.
We acknowledge that the correction factor based on the
experimentally deduced BMI correction curve might not be
applicable for individuals with strikingly different body com-
positions, such as body-builders. However, it is not clear,
again, that either bioelectric impedance or DEXA would
provide a better index of Gd(DTPA)2 blood levels. For these
studies, we recommend directly measuring blood levels of
Gd(DTPA)2 through blood sampling and Gd(DTPA)2
quantitation via inductively coupled plasma emission spec-
trophotometry (available commercially) or nuclear magnetic
resonance (NMR) spectroscopy (available in many aca-
demic centers).
The second aspect of our original paper was the
measurement of the dGEMRIC Index as a function of
BMI, after correcting for dose bias. The potential correla-
tions of dGEMRIC with other factors which may inﬂuence
OA, such as fat vs skeletal muscle mass, are interesting
questions for further study.
In summary, implementation of a compensation factor for
dose bias in dGEMRIC studies (1) will not be needed for
longitudinal analyses in which BMI does not change
signiﬁcantly over the course of the study, (2) should be
implemented as experimentally derived in the earlier study
for cross-sectional studies with a large range of BMI, and
(3) should be measured directly in studies which are done
particularly to assess the effects of varying body
composition on the dGEMRIC Index.
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